MedTrace Logo

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.

Conditions

Interventions

DRUG

SAR442970

1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial

DRUG

Placebo

1 mL extractable volume of placebo filled in 2 mL glass vial

Sponsors & Collaborators

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2024-08-22
Completion
2025-01-09
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Chile
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849922 on ClinicalTrials.gov